PPARγ agonism is used clinically to reduce insulin resistance and improve hyperglycemia associated with type 2 diabetes [59], however, this treatment markedly elevates TG levels in the liver associated with a number of murine models of diabetes or obesity [13,60]. This evidence concerns the gene PPARG and Insulin resistance.